ट्रेड Vir Biotechnology VIR

बेचें
 खरीदें

VirBiotechnology लाइव चार्ट

5m 15m 30m 1h 4h 1d 1w

उपकरण मूल बातें

Weekly Search
Weekly
Daily
दिनांक बंद करें परिवर्तन (%) परिवर्तित करें खुला उच्च कम

VirBiotechnology news

नवीनतम समाचार

और दिखाएं
Noah Lee 2025 Aug 07, 15:20

Waller Emerges as Potential Fed Chair Nominee Amidst Trump Considerations

Emma Rose 2025 Aug 07, 14:20

US Jobless Claims Rise: Analyzing Labor Market Trends and Economic Impact

Noah Lee 2025 Aug 07, 13:20

Trump-Putin Talks Fuel Ukraine Asset Rally Amid Peace Hope

Noah Lee 2025 Aug 07, 11:20

Netanyahu Seeks Approval for Full Israeli Occupation of Gaza: Implications and Analysis

Noah Lee 2025 Aug 07, 09:20

The Dollar Squeeze: How Rate Cuts Impact International Investors

Sophia Claire 2025 Aug 07, 09:20

Putin and Trump Meeting Possible Next Week Amid Ukraine Tensions: Kremlin

Noah Lee 2025 Aug 07, 06:20

Bank of England Expected to Cut Rates Amid Inflation Concerns and Slowing Growth

Ava Grace 2025 Aug 07, 05:20

Israel Gaza Conflict: Is a New Offensive on the Horizon?

जानकारी

स्प्रेड

0.03

स्प्रेड (%)

0.7026 %

लीवरेज

1:10

ओवरनाइट ब्याज विक्रय

-0.0597 %

overnight_interest_sell

-0.0292 %

मुद्रा

USD

ट्रेडिंग घंटे

बाज़ार बंद है

शुक्रवार

13:31 - 19:59

सोमवार

13:31-19:59

मंगवार

13:31-19:59

बुधवार

13:31-19:59

गुरुवार

13:31-19:59

विश्लेषण और सांख्यिकी

खुला

---

पिछला बंद

---

52 सप्ताह उच्च/निम्न्च

--- – ---

बाज़ार आकार

706394304

बकाया शेयर

138238000

प्राप्ति की तिथि (आगे)

0000-00-00

लाभांश आय 

पूर्व-लाभांश तिथि

अग्रिम वार्षिक लाभांश दर 

0

अग्रिम वार्षिक लाभांश आय

0

EPS

-4.23

इस उपकरण के बारे में अधिक जानें

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

संबंधित उपकरण

संपत्ति
बेचें
खरीदें
(%) परिवर्तित करें

अब ट्रेड करें

अब ट्रेड करें

अब ट्रेड करें

अब ट्रेड करें
view_all_instruments

latest_education_articles

और दिखाएं
Trustpilot